[Use of defibrotide in the treatment of Raynaud's phenomenon associated with progressive systemic sclerosis or essential mixed cryoglobulinemia].
Ranieri
G
G
De Mitrio
V
V
Petronelli
M
M
Ancona
A
A
Dammacco
F
F
D000293:Adolescent; D000328:Adult; D003449:Cryoglobulinemia / Q000150:complications*; D004341:Drug Evaluation; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000150:complications / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000150:complications*
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide
Impiego del defibrotide nel trattamento del fenomeno di Raynaud associato a sclerosi sistemica progressiva o crioglobulinemia mista essenziale.